Quantitative Justification of the Change From 10% to 30% for Human Epidermal Growth Factor Receptor 2 Scoring in the American Society of Clinical Oncology/College of American Pathologists Guidelines: Tumor Heterogeneity in Breast Cancer and Its Implications for Tissue Microarray Based Assessment of Outcome
Moeder, C. B., Giltnane, J. M., Harigopal, M., Molinaro, A., Robinson, A., Gelmon, K., Huntsman, D., Camp, R. L., Rimm, D. L.Volume:
25
Language:
english
Journal:
Journal of Clinical Oncology
DOI:
10.1200/JCO.2007.12.8033
Date:
December, 2007
File:
PDF, 343 KB
english, 2007